Skip to main content
Premium Trial:

Request an Annual Quote

Pathomiq, Neuberg Diagnostics Partner to Launch Prostate Cancer Recurrence Test

NEW YORK — Pathomiq has partnered with laboratory services provider Neuberg Diagnostics to commercialize a machine learning-based tool for the prediction of prostate cancer recurrence, the companies said on Tuesday.

Under the terms of the alliance, the companies aim to roll out Pathomiq's Pathomiq-PRAD as a laboratory-developed test in the US, followed by other international markets. The test is designed to analyze digitized H&E radical prostatectomy whole-slide images to assess a patient's risk of biochemical relapse and metastasis, as well as their likelihood of benefiting from adjuvant therapy such as salvage radiation therapy and androgen-deprivation therapy.

Financial and other terms of the deal were not disclosed.

"Our Pathomiq-PRAD AI model has been successfully validated at multiple medical institutions and pharmaceutical partners, and we are excited to make it clinically available soon through our partnership with Neuberg Diagnostics," Pathomiq Chief Medical Officer George Wilding said in a statement.

Early last year, Cupertino, California-based Pathomiq and academic collaborators published data demonstrating the use of the firm's platform to predict prostate cancer recurrence.